Technical Analysis for NKTR - Nektar Therapeutics

Grade Last Price % Change Price Change
grade A 83.43 1.57% 1.29
NKTR closed up 1.57 percent on Friday, February 16, 2018, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
7 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical NKTR trend table...

Date Alert Name Type % Chg
Feb 16 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Feb 16 180 Bullish Setup Bullish Swing Setup 0.00%
Feb 16 Boomer Buy Setup Bullish Swing Setup 0.00%
Feb 16 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Feb 16 Calm After Storm Range Contraction 0.00%
Feb 16 Narrow Range Bar Range Contraction 0.00%
Feb 16 NR7 Range Contraction 0.00%
Feb 16 Inside Day Range Contraction 0.00%
Feb 16 Wide Bands Range Expansion 0.00%
Feb 15 1,2,3 Pullback Bullish Bullish Swing Setup 1.57%

Older signals for NKTR ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its product pipeline consists of drug candidates in various therapeutic areas, including oncology, pain, anti-infectives, and immunology. The company's drug candidates in clinical development stage comprise naloxegol, an opioid antagonist that is in Phase 3 clinical trail for the treatment of opioid-induced constipation; BAY41-6551 that has completed Phase 2 clinical trail to treat gram-negative pneumonias; NKTR-181, a mu-opioid analgesic molecule, which is in Phase 2 clinical trail for chronic pain; and NKTR-192 that is in Phase 1 to treat acute pain. Its other product candidates comprise etirinotecan pegol, a topoisomerase I inhibitor, which is in Phase 3 clinical trial for the treatment of metastatic breast cancer; in Phase 2 clinical trail for ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat metastatic colorectal cancer that completed Phase I clinical trial. In addition, the company offers preclinical drug candidates comprising opioid/NKTR-118 for the treatment of chronic pain; NKTR-171 to treat neuropathic pain; and NKTR-214, a cytokine immunostimulatory therapy for the treatment of oncology. Nektar Therapeutics has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. Further, it has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, MAP Pharmaceuticals, Merck, Pfizer, Roche, and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.
Is NKTR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 99.02
52 Week Low 12.5
Average Volume 2,526,052
200-Day Moving Average 35.2106
50-Day Moving Average 68.3894
20-Day Moving Average 80.3675
10-Day Moving Average 79.096
Average True Range 6.1011
ADX 48.19
+DI 28.8
-DI 13.64
Chandelier Exit (Long, 3 ATRs ) 80.7167
Chandelier Exit (Short, 3 ATRs ) 86.4533
Upper Bollinger Band 88.855
Lower Bollinger Band 71.88
Percent B (%b) 0.68
BandWidth 21.121722
MACD Line 3.5952
MACD Signal Line 4.2641
MACD Histogram -0.6689
Fundamentals Value
Market Cap 13.04 Billion
Num Shares 156 Million
EPS -1.40
Price-to-Earnings (P/E) Ratio -59.59
Price-to-Sales 27.79
Price-to-Book 1075.45
PEG Ratio 3.31
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 87.47
Resistance 3 (R3) 87.21 85.62 86.79
Resistance 2 (R2) 85.62 84.59 85.74 86.57
Resistance 1 (R1) 84.52 83.95 85.07 84.78 86.34
Pivot Point 82.93 82.93 83.20 83.05 82.93
Support 1 (S1) 81.83 81.90 82.38 82.09 80.52
Support 2 (S2) 80.24 81.26 80.36 80.29
Support 3 (S3) 79.14 80.24 80.07
Support 4 (S4) 79.40